PERSERIS KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PERSERIS KIT (PERSERIS KIT).
Risperidone, the active component of PERSERIS, is an atypical antipsychotic with antagonist activity at dopamine D2 and serotonin 5-HT2A receptors. It also binds to α1-adrenergic, α2-adrenergic, and histamine H1 receptors.
| Metabolism | Risperidone is extensively metabolized in the liver via CYP2D6 and CYP3A4 isoenzymes to 9-hydroxyrisperidone (paliperidone), the major active metabolite. |
| Excretion | Primarily hepatic metabolism via CYP2D6 and CYP3A4; approximately 30-40% of a dose is excreted in urine as metabolites, with less than 1% as unchanged drug. Biliary/fecal elimination accounts for about 60-70%. |
| Half-life | Terminal elimination half-life is approximately 15 days (range 10-20 days) for the extended-release injectable formulation, reflecting slow release from the depot and sustained plasma concentrations. |
| Protein binding | Approximately 95% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution is about 7-10 L/kg, indicating extensive extravascular distribution and high tissue binding. |
| Bioavailability | Subcutaneous injection: 100% for the sustained-release formulation. Immediate-release oral formulations have approximately 40% bioavailability due to first-pass metabolism, but the depot is fully absorbed. |
| Onset of Action | Subcutaneous injection: Clinical antipsychotic effect is typically observed within 4-7 days post-injection, aligning with the attainment of steady plasma levels. |
| Duration of Action | Following a single 90 mg or 120 mg subcutaneous injection, therapeutic plasma concentrations are maintained for approximately 1 month, supporting monthly dosing intervals. |
| Molecular Weight | 410.5 |
Subcutaneous injection: 90 mg every 28 days for maintenance treatment of schizophrenia.
| Dosage form | FOR SUSPENSION, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Severe renal impairment (CrCl <30 mL/min) has not been studied; use with caution. |
| Liver impairment | Mild hepatic impairment (Child-Pugh A): No dose adjustment; moderate to severe (Child-Pugh B or C): Not studied; avoid use. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | Elderly patients (≥65 years): Dose selection should be cautious, starting at the low end of the dosing range, reflecting greater frequency of decreased hepatic, renal, or cardiac function and concomitant disease or other drug therapy. |
| 1st trimester | Avoid use; insufficient human data; animal studies show fetal toxicity at doses lower than human therapeutic equivalent. |
| 2nd trimester | Avoid use; no well-controlled studies; potential risk of extrapyramidal symptoms and withdrawal in neonate. |
| 3rd trimester | Avoid use; use in third trimester may cause extrapyramidal and/or withdrawal symptoms in neonate. |
Clinical note
Comprehensive clinical and safety monograph for PERSERIS KIT (PERSERIS KIT).
| Placental transfer | Risperidone crosses the placenta; measurable levels found in cord blood and amniotic fluid. |
| Breastfeeding | Risperidone is excreted in human milk; consider the developmental and health benefits of breastfeeding along with the mother's clinical need and potential adverse effects on the breastfed child. |
■ FDA Black Box Warning
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. PERSERIS is not approved for the treatment of patients with dementia-related psychosis.
| Serious Effects |
Known hypersensitivity to risperidone or any component of the formulation
| Precautions | Cerebrovascular adverse events in elderly patients with dementia-related psychosis, Neuroleptic malignant syndrome (NMS), Tardive dyskinesia, Hyperglycemia and diabetes mellitus, Orthostatic hypotension, Leukopenia, neutropenia, and agranulocytosis, Seizures, QT interval prolongation, Weight gain and metabolic changes |
| Food/Dietary | No significant food interactions. Avoid grapefruit and grapefruit juice as they may alter drug metabolism. Maintain adequate hydration to prevent constipation. Limit intake of high-fat meals as they may increase drug absorption. |
Loading safety data…
| Lactation Rating |
| L4 (Possibly Hazardous) |
| Teratogenic Risk | PERSERIS (risperidone) is Pregnancy Category C. First trimester: Limited data; animal studies show increased fetal resorptions and malformations at doses >2 times human dose. Second and third trimesters: Cases of extrapyramidal symptoms and withdrawal (e.g., agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder) in neonates exposed during late pregnancy. Neonatal monitoring recommended. |
| Fetal Monitoring | Monitor maternal blood pressure and weight gain. Assess for gestational diabetes due to risk of hyperglycemia. Fetal monitoring for growth and development; third trimester ultrasound for macrosomia. Neonatal assessment for extrapyramidal symptoms, withdrawal, and respiratory distress at birth. |
| Fertility Effects | Risperidone may elevate prolactin levels via dopamine D2 blockade, leading to galactorrhea, amenorrhea, anovulation, and reduced fertility in females. No direct effect on sperm parameters reported; reversible upon dose reduction or discontinuation. |
| Clinical Pearls | Administer exclusively via subcutaneous injection in the abdomen. Rotate injection sites. Do not massage the injection site. Tap the product pack to dislodge product before reconstitution. Use the provided 21G 1-inch needle for reconstitution and the 20G 1.5-inch needle for injection. Discard unused portion after 24 hours at room temperature. Monitor for injection site reactions, extrapyramidal symptoms, and tardive dyskinesia. Antipsychotic efficacy may take several weeks to fully manifest. |
| Patient Advice | This medication is injected monthly under the skin of your abdomen by a healthcare provider. · Do not rub or massage the injection site. You may experience some pain, redness, or swelling at the injection site. · Report any unusual muscle movements, stiffness, or restlessness to your doctor immediately. · This medicine may cause dizziness or drowsiness. Avoid driving or operating machinery until you know how it affects you. · Avoid alcohol and marijuana while using this medication as they can increase side effects. · Tell your doctor if you become pregnant or plan to become pregnant during treatment. |